Apollo Hospitals (AHEL) Q2 FY26 Financial Performance & Business Update

Key Highlights: Robust All-Round Performance Surpasses Estimates Apollo Hospitals Enterprise Ltd. (AHEL) has delivered a strong operational and financial performance for the second quarter ending September 30, 2025. Consolidated Financial Performance (Q2 FY26 vs. Q2 FY25) Net Profit: Grew 25% YoY to ₹494 crore (vs. ₹395 crore), significantly exceeding street estimates of ₹426.6 crore. Revenue from Operations: Increased 12.8% YoY to ₹6,303 crore (vs. ₹5,589 crore), ahead of the projected ₹6,231.7 crore. Operating Profit (EBITDA): Rose 15.4% YoY to ₹941 crore. EBITDA Margin: Expanded by 30 basis points (bps) to 14.9% (vs. 14.6%), outperforming expectations of 14.1% and signaling strong operational efficiency. Segmental Performance Analysis 1. Healthcare Services (Core Business): Demonstrated steady growth with revenue rising 9% YoY to ₹3,169 crore. The segment maintained robust profitability, reporting an EBITDA of ₹781 crore at a healthy margin of 24.6%. 2. Apollo HealthCo (Digital Health & Pharmacy): This high-growth segment was a key performance driver, with revenue climbing 17% YoY to ₹2,661 crore. EBITDA more than doubled to ₹110 crore, reflecting significant operational leverage and scaling benefits from the expanding digital platform and pharmacy network. 3. Apollo Health and Lifestyle (AHLL - Clinics & Diagnostics): The segment registered strong momentum with a 17% YoY increase in revenue to ₹474 crore. EBITDA grew at a faster pace of 21% YoY to ₹50 crore, indicating improved profitability. Strategic & Operational Developments Network Expansion: AHEL continued its strategic expansion by launching Athenaa in New Delhi, noted as Asia’s first dedicated cancer center for women. The group also enhanced its tertiary care presence with the opening of Royal Mudhol Apollo Hospitals in Pune.